Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: A North American open-label study

Annals of Allergy, Asthma and Immunology

Volumn 110, Issue 4, 2013, Pages 295-299

  Riedl, Marc A ^a   Levy, Robyn J ^b   Suez, Daniel ^c   Lockey, Richard F ^d   Baker, James W ^e   Relan, Anurag ^f   Zuraw, Bruce L ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Family Allergy and Asthma Center   (United States)

^c Allergy Asthma and Immunology Clinic   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e Baker Asthma Allergy and Dermatology   (United States)

^f Pharming Group NV   (Netherlands)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR;

ADOLESCENT; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FEMALE; HUMAN; HYPOTENSION; IMMUNOGENICITY; LIP ITCHING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REPEAT PROCEDURE; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SOFT PALATE ITCHING; TREATMENT RESPONSE; UROSEPSIS; URTICARIA; VERTIGO; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INHIBITOR PROTEIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875436177     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2013.02.007     Document Type: Article

References (16)

1. B.L. Zuraw Clinical practice: hereditary angioedema N Engl J Med 359 2008 1027 1036
2. A. Agostoni, and M. Cicardi Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients Medicine 71 1992 206 215
3. K. Bork, G. Meng, P. Staubach, and J. Hardt Hereditary angioedema: new findings concerning symptoms, affected organs, and course Am J Med 119 2006 267 274 (Pubitemid 43255068)
4. M. Cicardi, and A. Zanichelli Angioedema due to C1 inhibitor deficiency in 2010 Intern Emerg Med 5 2010 481 486
5. T.J. Craig, R.J. Levy, and R.L. Wasserman Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks J Allergy Clin Immunol 124 2009 801 808
6. M. Kunschak, W. Engl, and F. Maritsch A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema Transfusion 38 1998 540 549 (Pubitemid 28317229)
7. A.T. Waytes, F.S. Rosen, and M.M. Frank Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate N Engl J Med 334 1996 1630 1634 (Pubitemid 26192522)
8. B. Zuraw, M. Cicardi, and R.J. Levy Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema J Allergy Clin Immunol 126 2010 821 827.e14
9. B.L. Zuraw, P.J. Busse, and M. White Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema N Engl J Med 363 2010 513 522
10. H.A. van Veen, J. Koiter, and C.J. Vogelezang Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits J Biotechnol 162 2012 319 326
11. C.V. McMillan, J. Speight, A. Relan, L. Bellizzi, G. Haase, and M. Cicardi Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study Patient 5 2012 113 126
12. C.E. Hack, M. Mannesse, A. Baboeram, B. Oortwijn, and A. Relan Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies BioDrugs 26 2012 303 313
13. T.J. Craig, A.K. Bewtra, and S.L. Bahna C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks: final results of the I.M.P.A.C.T.2 study Allergy 66 2011 1604 1611
14. L. Varga, G. Füst, D. Csuka, and H. Farkas Treatment with C1-inhibitor concentrate does not induce IgM type anti-C1 inhibitor antibodies in patients with hereditary angioedema Mol Immunol 48 2011 572 576
15. D. Moldovan, A. Reshef, and J. Fabiani Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study Clin Exp Allergy 42 2012 929 935
16. Hack CE, Relan A, Baboeram A, et al. Immuno-safety of recombinant human C1-inhibitor in hereditary angioedema: no evidence for IgE responses. Clin Drug Investig. In press.